1 A de®ciency of constitutive nitric oxide synthase (cNOS)-derived nitric oxide (NO), due to reduced availability of L-arginine, importantly contributes to allergen-induced airway hyperresponsiveness (AHR) after the early asthmatic reaction (EAR). Since cNOS and arginase use L-arginine as a common substrate, we hypothesized that increased arginase activity is involved in the allergeninduced NO de®ciency and AHR. 2 Using a guinea-pig model of allergic asthma, we addressed this hypothesis by examining the e ects of the speci®c arginase inhibitor N o -hydroxy-nor-L-arginine (nor-NOHA) on the responsiveness to methacholine of isolated perfused tracheae from unchallenged control animals and from animals 6 h after ovalbumin challenge. Arginase activity in these preparations was investigated by measuring the conversion of L-[ 14 C]arginine to [ 14 C]urea. 3 Airways from allergen-challenged animals showed a 2 fold (P50.001) increase in responsiveness to intraluminal (IL) administration of methacholine compared to controls. A similar hyperresponsiveness (1.8 fold, P50.01) was observed in control airways incubated with the NOS inhibitor N onitro-L-arginine methyl ester (L-NAME, 0.1 mM, IL), while L-NAME had no further e ect on the airways from challenged animals. 4 Remarkably, 5 mM nor-NOHA (IL) normalized the hyperresponsiveness of challenged airways to basal control (P50.001), and this e ect was fully reversed again by 0.1 mM L-NAME (P50.05). Moreover, arginase activity in homogenates of the hyperresponsive airways was 3.5 fold (P50.001) enhanced compared to controls. 5 The results indicate that enhanced arginase activity contributes to allergen-induced de®ciency of cNOS-derived NO and AHR after the EAR, presumably by competition with cNOS for the common substrate, L-arginine. This is the ®rst demonstration that arginase is involved in the pathophysiology of asthma. British Journal of Pharmacology (2002) 136, 391 ± 398 Keywords: Arginase; constitutive nitric oxide synthase; nitric oxide; methacholine; N o -hydroxy-nor-L-arginine; allergic asthma; early asthmatic reaction; airway hyperresponsiveness; tracheal perfusion; guinea-pig Abbreviations: AHR, airway hyperreactivity; cNOS, constitutive nitric oxide synthase; EAR, early asthmatic reaction; EL, extraluminal; E max , maximal e ect; eNOS, endothelial nitric oxide synthase; IL, intraluminal; iNANC, inhibitory nonadrenergic noncholinergic; iNOS, inducible nitric oxide synthase; KH, Krebs-Henseleit; LAR, late asthmatic reaction; L-NAME, N o -nitro-L-arginine methyl ester; L-NMMA, N G -monomethyl-L-arginine; nNOS, neuronal nitric oxide synthase; nor-NOHA, N o -hydroxy-nor-L-arginine; DP, di erential (hydrostatic) pressure; P inlet , (hydrostatic) pressure at the inlet; P outlet , (hydrostatic) pressure at the outlet; pEC 50 , 7log 10 of the concentration causing 50% of the e ect
1 Cholinergic airway constriction is functionally antagonized by agonist-induced constitutive nitric oxide synthase (cNOS)-derived nitric oxide (NO). Since cNOS and arginase, which hydrolyzes Larginine to L-ornithine and urea, use L-arginine as a common substrate, competition between both enzymes for the substrate could be involved in the regulation of cholinergic airway reactivity. Using a perfused guinea-pig tracheal tube preparation, we investigated the modulation of methacholineinduced airway constriction by the recently developed, potent and speci®c arginase inhibitor N ohydroxy-nor-L-arginine (nor-NOHA). 2 Intraluminal (IL) administration of nor-NOHA caused a concentration-dependent inhibition of the maximal e ect (E max ) in response to IL methacholine, which was maximal in the presence of 5 mM nor-NOHA (E max =31.2+1.6% of extraluminal (EL) 40 mM KCl-induced constriction versus 51.6+2.1% in controls, P50.001). In addition, the pEC 50 (7log 10 EC 50 ) was slightly but signi®cantly reduced in the presence of 5 mM nor-NOHA. 3 The inhibition of E max by 5 mM nor-NOHA was concentration-dependently reversed by the NOS inhibitor N o -nitro-L-arginine methyl ester (L-NAME), reaching an E max of 89.4+7.7% in the presence of 0.5 mM L-NAME (P50.01). A similar E max in the presence of 0.5 mM L-NAME was obtained in control preparations (85.2+9.7%, n.s.). 4 In the presence of excess of exogenously applied L-arginine (5 mM), 5 mM nor-NOHA was ine ective (E max =33.1+5.8 versus 31.1+7.5% in controls, n.s.). 5 The results indicate that endogenous arginase activity potentiates methacholine-induced airway constriction by inhibition of NO production, presumably by competition with cNOS for the common substrate, L-arginine. This ®nding may represent an important novel regulation mechanism of airway reactivity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.